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Figure S1. H&E staining of the tumors from M2 MPNST-bearing B6129SF1/J mice that were: a) Untreated,
b) PD901-treated: 5 mg/kg PD901, c) PTT-treated: 1.0 mg/mL PBNPs at 1.5 W/cm2 using an 808 nm NIR
laser, or d) PD901 + PTT-treated: both PD901 and PTT treatments using identical treatment conditions for
each individual therapy. Tumors were extracted 8 h after treatment.
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SUPPLEMENTARY TABLE 1: List of p-values in this study 
Figure 1c 
Annexin V+ 7AAD- p-value 
Vehicle vs. 0.1 μM PD901 0.004 
0.1 μM PD901 vs. 1 μM PD901 0.023 
1 μM PD901 vs. 10 μM PD901 0.001 
7AAD+ p-value 
Vehicle vs. 0.1 μM PD901 3.11E-04 
0.1 μM PD901 vs. 1 μM PD901 0.321 
1 μM PD901 vs. 10 μM PD901 0.008 
Figure 1d 
G0/G1 p-value 
Vehicle vs. 0.1 μM PD901 0.018 
Vehicle vs. 1 μM PD901 0.001 
Vehicle vs. 10 μM PD901 0.001 
0.1 μM PD901 vs. 1 μM PD901 0.003 
0.1 μM PD901 vs. 10 μM PD901 0.003 
1 μM PD901 vs. 10 μM PD901 0.031 
Figure 2b 
Temperature after 10 minutes p-value 
Vehicle vs. 0.1 mg/mL 0.105 
0.01 mg/mL vs. 0.02 mg/mL 0.025 
0.02 mg/mL vs. 0.03 mg/mL 0.049 
0.03 mg/mL vs. 0.04 mg/mL 0.111 
0.04 mg/mL vs. 0.05 mg/mL 0.122 
0.05 mg/mL vs. 0.1 mg/mL 1.28E-04 
0.1 mg/mL vs. 1.0 mg/mL 1.18E-05 
Figure 2c 
Viability (+ 1.5 W/cm2) p-value 
Vehicle vs. 0.01 mg/mL 0.048 
Vehicle vs. 0.02 mg/mL 3.55E-05 
Vehicle vs. 0.03 mg/mL 3.54E-06 
Vehicle vs. 0.04 mg/mL 3.01E-04 
Vehicle vs. 0.05 mg/mL 4.80E-05 
Figure 2d 
Annexin V+ 7AAD- p-value 
0.03 mg/mL vs. Vehicle 0.002 
0.03 mg/mL vs. 1.5 W/cm2 0.002 
0.03 mg/mL vs. 0.01 mg/mL 0.007 
0.03 mg/mL vs. 0.05 mg/mL 0.001 
7AAD+ p-value 
0.05 mg/mL vs. Vehicle 9.28E-05 
0.05 mg/mL vs. 1.5 W/cm2 9.35E-05 
0.05 mg/mL vs. 0.01 mg/mL 0.039 
0.05 mg/mL vs. 0.03 mg/mL 0.001 
Figure 3a 
Viability p-value 
LOW Combo vs. LOW PD901 0.029 
LOW Combo vs. LOW PTT 0.002 
HIGH Combo vs. HIGH PD901 0.009 
HIGH Combo vs. HIGH PTT 0.024 
Figure 4b 
Survival p-value 
Untreated vs. PTT 0.220 
Untreated vs. PD901 0.003 
Untreated vs. Combo 0.003 
PTT vs. PD901 0.400 
PTT vs. Combo 0.006 
PD901 vs. Combo 0.003 
